Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
CSPC Pharmaceutical Group (01093.HK) HB1901 Clinical Study Meets Primary Efficacy Endpoint
Recommend 7 Positive 7 Negative 4 |
||||
|
||||
|
CSPC Pharmaceutical Group (01093.HK) announced that the Ib/III clinical study of its self-developed sirolimus for injection (albumin-bound) (HB1901) for the treatment of advanced malignant perivascular epithelioid cell tumor (PEComa) has successfully met its pre-specified primary efficacy endpoint, demonstrating statistically significant differences and clear clinical benefits. The company stated that HB1901 has shown outstanding efficacy and is expected to fill the domestic treatment gap for this indication, potentially becoming the first standard-of-care therapy in China for advanced malignant PEComa. In February last year, HB1901 was granted Breakthrough Therapy Designation by the National Medical Products Administration. Currently, multiple clinical trials exploring the efficacy and safety of sirolimus for injection (albumin-bound) in combination with different drugs across various tumor types are progressing steadily. (ss/da) This article was automatically translated by AI, the Chinese version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation. Auto-translated by AI AASTOCKS Financial News |
||||
Copied to Clipboard
 |
||||
